| Symbol | FHTX |
|---|---|
| Name | FOGHORN THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 500 TECHNOLOGY SQUARE,SUITE 700, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 617 586-3100 |
| Fax | — |
| — | |
| Website | https://www.foghorntx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001822462 |
| Description | Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors. Additional info from NASDAQ: |
(80% Positive) FOGHORN THERAPEUTICS INC. (FHTX) Announces Enrollment Update for escalation Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreNew Form ARS - Foghorn Therapeutics Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-193958 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - Foghorn Therapeutics Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-193948 <b>Size:</b> 337 KB
Read moreNew Form DEF 14A - Foghorn Therapeutics Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-193928 <b>Size:</b> 2 MB
Read moreFoghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Read moreGOTTSCHALK ADRIAN 🟡 adjusted position in 0 shares of Foghorn Therapeutics Inc. (FHTX) Transaction Date: Apr 09, 2026 | Filing ID: 000005
Read moreFoghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Read moreNew Form S-8 - Foghorn Therapeutics Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001628280-26-021405 <b>Size:</b> 224 KB
Read more(90% Positive) FOGHORN THERAPEUTICS INC. (FHTX) Announces Enrollment Update for financing Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07551635 | SMARCA4/2 Inhibitor for POU2F3-Positive SCLC | Phase2 | Small Cell Lung Cancer | Not_Yet_Recruiting | 2026-09-04 | 2029-01-31 | ClinicalTrials.gov |
| NCT07283094 | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myelo… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2026-02-03 | 2030-02-01 | ClinicalTrials.gov |
| NCT04965753 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tum… | Phase1 | Advanced Synovial Sarcoma | Terminated | 2021-08-17 | 2023-12-04 | ClinicalTrials.gov |
| NCT04891757 | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematol… | Phase1 | Advanced Hematologic Malignancy | Active_Not_Recruiting | 2021-06-14 | 2027-06-01 | ClinicalTrials.gov |
| NCT04879017 | FHD-286 in Subjects With Metastatic Uveal Melanoma | Phase1 | Metastatic Uveal Melanoma | Terminated | 2021-05-11 | 2023-11-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| FHD-286 | Other | Phase PHASE1 | Metastatic Uveal Melanoma | TERMINATED | NCT04879017 |
| FHD-609 | Other | Phase PHASE1 | Advanced Synovial Sarcoma | TERMINATED | NCT04965753 |
| Decitabine | Other | Phase PHASE1 | Advanced Hematologic Malignancy | ACTIVE_NOT_RECRUITING | NCT04891757 |
| Low Dose Cytarabine | Other | Phase PHASE1 | Advanced Hematologic Malignancy | ACTIVE_NOT_RECRUITING | NCT04891757 |
| FHD-286 | Other | Phase PHASE1 | Advanced Hematologic Malignancy | ACTIVE_NOT_RECRUITING | NCT04891757 |
| FHD-286 | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |
| Decitabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| Venetoclax | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |
| FHD-609 | DRUG | Phase PHASE1 | Advanced Synovial Sarcoma | TERMINATED | NCT04965753 |
| Decitabine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |
| Low Dose Cytarabine | DRUG | Phase PHASE1 | Advanced Hematologic Malignancy | ACTIVE_NOT_RECRUITING | NCT04891757 |
| FHD-286 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |